Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teslanbaicin for Radiation Proctitis
NCT06974123Phase 2Enrolling by invitation
- Sponsor
- Xinxiang Medical University First Affiliated Hospital
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of teslanbaicin in radiation proctitis, sponsored by Xinxiang Medical University First Affiliated Hospital. Primary endpoint: Safety of oral administration of Teslancure at 8 weeks. Started Oct 2024; status: enrolling by invitation.
02
Drugs
teslanbaicin
03
Conditions
radiation proctitis
Beyond the preview
Go deeper on NCT06974123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06974123.